

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 12, 2025

University of Colorado Anschutz Medical Campus Cancer Center Bioinformatics Core Facility

RRID:SCR_021983

Type: Tool

Proper Citation

University of Colorado Anschutz Medical Campus Cancer Center Bioinformatics Core Facility
(RRID:SCR_021983)

Resource Information

URL: <https://medschool.cuanschutz.edu/bioinformaticssr>

Proper Citation: University of Colorado Anschutz Medical Campus Cancer Center
Bioinformatics Core Facility (RRID:SCR_021983)

Description: Cancer focused bioinformatics group that assists in all needs related to omics and big data. We assist our collaborators with experimental design, data processing, interpretation, generating publication-quality figures, and preparing manuscripts and grants.

Abbreviations: BioinformaticsBBSR

Synonyms: Bioinformatics - Biostatistics and Bioinformatics Shared Resource

Resource Type: access service resource, core facility, service resource

Keywords: ABRF, USEDit, cancer omics and big data bioinformatics services

Funding:

Resource Name: University of Colorado Anschutz Medical Campus Cancer Center
Bioinformatics Core Facility

Resource ID: SCR_021983

Alternate IDs: ABRF_1305

Alternate URLs: <https://coremarketplace.org/?FacilityID=1305>

Record Creation Time: 20220421T050138+0000

Record Last Update: 20250412T060421+0000

Ratings and Alerts

No rating or validation information has been found for University of Colorado Anschutz Medical Campus Cancer Center Bioinformatics Core Facility.

No alerts have been found for University of Colorado Anschutz Medical Campus Cancer Center Bioinformatics Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

DeGolier KR, et al. (2025) Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response. *Nature immunology*, 26(1), 68.

Iwanaga R, et al. (2024) Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. *Cancer research communications*, 4(8), 1919.

Wu MH, et al. (2024) Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8+ T cell adoptive therapies in pre-clinical studies. *Nature communications*, 15(1), 4444.

Veo B, et al. (2024) Single-cell multi-omics analysis identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma. *Research square*.

Hughes CJ, et al. (2023) SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma. *Nature communications*, 14(1), 4357.

Corr BR, et al. (2023) Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1 -mutated endometrial cancer. *bioRxiv : the preprint server for biology*.

Vragel G, et al. (2023) Murine Gammaherpesvirus 68 Efficiently Infects Myeloid Cells

Resulting In An Atypical, Restricted Form Of Infection. bioRxiv : the preprint server for biology.

DeGolier KR, et al. (2023) Antigen experience history directs distinct functional states of CD8+ CAR T cells during the anti-leukemia response. Research square.

Wolin AR, et al. (2023) EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro-oncology, 25(12), 2287.

Pei S, et al. (2023) A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer discovery, 13(9), 2032.

Rinaldetti S, et al. (2022) High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes. International journal of molecular sciences, 23(18).